REMARKS

Support for the amendments to claim 1, can be found in Applicants' published application at page 1, paragraph 0018; page 2, paragraphs 0032,0033 and 0035; page 3, paragraph 0042 and example 1.3. Support for new claim 21 can be found, for example, in original claim 8 and at page 6, paragraph 0090 of Applicants' published application. Support for new claim 22 can be found, for example, at page 6, paragraph 0093 and Table 2 of Applicants published application. Support for new claim 23 can be found, for example, at page 6, paragraph 0091 of Applicants published application. Support for new claim 24 can be found, for example, at page 5, paragraph 0089 and Example 2 of Applicants' published application. Support for new claim 25 can be found, for example, at page 3, paragraph 0047-0048 of Applicants' published application. No new matter has been added.

Rejections under 35 USC §102/103

Claim 1 is rejected under 35 U.S.C. 102(b) as allegedly being anticipated by WO01/77660. (Cabrera et al., US 6,863,820, is relied on as an equivalent form of WO01/77660). Claims 2, 3, and 14-18 are rejected under 35 U.S.C. 103(a) as allegedly being unpatentable over WO01/77660 and further in view of WO 98/58253. (Cabrera et al, US 6,863,820, is relied on as an equivalent form of WO98/58253). Claims 1, 2, 4, 5, 14, 16, 17 and 19 are rejected under 35 U.S.C. 102(b) as allegedly being anticipated by EP 838 257. Claims 3, 15, and 18 and rejected under 35 U.S.C. 103(a) as allegedly being unpatentable over EP 838 257, and further in view of WO 98/58253. Claims 12 and 13 are rejected under 35 U.S.C. 103(a) as allegedly being unpatentable over EP 838 257 e, and further in view of Dhingra et al (US 6,054,052). Claim 20 is rejected under 35 U.S.C. 103(a) as allegedly being unpatentable over EP 838 257, and further in view of Li et al (US 7,125,448). Claims 12 and 13 are rejected under 35 U.S.C. 103(a) as allegedly being unpatentable over WO 98/58253, and further in view of Dhingra et al (US 6,054,052):

It is believed that the amendments to the claims render the rejections moot. Neither Cabrera '820 nor EP 838257 disclose or suggest a moulding that is clad on the long side wherein the organic polymer is physicosorbed or chemisorbed on the inorganic moulding.

Furthermore, Cabrera '962, Dhingra et al and Li et al. do not cure the deficiencies of EP 838257.

Thus, it is respectfully requested that the rejections under 35 USC $\S102$ and $\S103$ be withdrawn.

No fee is believed to be due with this response, however, the Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

Anthony Zelaro Reg. No. 27,969

Attorney for Applicant(s)

Jennifer Branigan Reg. No. 40,921

Agent for Applicant(s)

MILLEN, WHITE, ZELANO

& BRANIGAN, P.C.

Arlington Courthouse Plaza 1, Suite 1400

2200 Clarendon Boulevard Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: Merck-3009

Date: 19 July 2007

K:\Merck\3000 - 3999\3009\Response to Restriction Requirement.doc